JPS61112027A - Carcinostatic agent - Google Patents

Carcinostatic agent

Info

Publication number
JPS61112027A
JPS61112027A JP59233310A JP23331084A JPS61112027A JP S61112027 A JPS61112027 A JP S61112027A JP 59233310 A JP59233310 A JP 59233310A JP 23331084 A JP23331084 A JP 23331084A JP S61112027 A JPS61112027 A JP S61112027A
Authority
JP
Japan
Prior art keywords
3pts
root
juzen
taiho
rhizome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP59233310A
Other languages
Japanese (ja)
Other versions
JPH0469618B2 (en
Inventor
Hitoshi Ito
均 伊藤
Keishiro Shimura
志村 圭志郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsumura and Co
Original Assignee
Tsumura Juntendo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsumura Juntendo Inc filed Critical Tsumura Juntendo Inc
Priority to JP59233310A priority Critical patent/JPS61112027A/en
Publication of JPS61112027A publication Critical patent/JPS61112027A/en
Publication of JPH0469618B2 publication Critical patent/JPH0469618B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE:JUZEN-TAIHO-TO (a Chinese herb tea) composed of OUGI (root of Astragalus huantchy), KEIHI (bark of Cinnamomum cassia), JIOU (root of Rehmannia glutinosa), SHAKUYAKU (root of Paeonia albiflora), SENKYU (rhizome of Cnidium officinale), JUTSU (rhizome of Atractylodes lancea), TOUKI (root of Angelica acutiloba), NINJIN (rhizome of Panax ginseng), BUKURYO (fungi of Pachyma hoelen) and KANZO (root of Glycyrrhiza glabra) is used as a carcinostatic agent free from side effects. CONSTITUTION:JUZEN-TAIHO-TO is used as a carcinostatic agent. It has been found that JUZEN-TAIHO-TO used as a Chinese herb tea for the diseases such as inappetence, fatigue and the development of physical strength after disease, etc., has carcinostatic effect. For example, 2.5-3pts. of OUGI, 3pts. of KEIHI, 3pts. of JIOU, 3pts. of SHAKUYAKU, 3pts. of SENKYU, 3pts. of JUTSU, 3pts. of TOUKI, 2.5-3pts. of NINJIN, 3pts. of BUKURYO and 1.5pts. of KANZO are extracted with 10 times weight of hot water, and the extract liquid is filtered and dried to obtain a dried extract powder of JUZEN-TAIHO- TO, which can be formed to tablet, capsule, etc., by conventional method. The agent increases the survival ratio of ICR male mouse of Ehrlich ascites carcinoma. Furthermore, it has extremely low toxicity and high safety.

Description

【発明の詳細な説明】 産業上の利用分野 本発明は制癌剤に関するものである。[Detailed description of the invention] Industrial applications The present invention relates to anticancer agents.

従来の技術 現在使用されている制癌剤はその薬理機構も明確で、す
ぐれた制癌作用をもつものが多いがその半面、正常細胞
にも作用して致命的な副作用をもたらすことら少なくな
い。従って、i+1作用が少ない制癌剤の開発が望まれ
ている。
2. Prior Art The pharmacological mechanisms of the anticancer drugs currently in use are well defined, and many of them have excellent anticancer effects, but on the other hand, they often act on normal cells and cause fatal side effects. Therefore, it is desired to develop an anticancer agent with less i+1 action.

発明が解決しようとする問題点 本発明は副作用の少ない、制癌剤を提供するらのである
Problems to be Solved by the Invention The present invention provides an anticancer agent with few side effects.

問題を解決するための手段 本発明者等は種々の漢方処方について制癌効果に関する
研究を行った結果、買置、桂皮、地黄、勺薬、用弓、嵐
、当帰、人参、決苓、甘草からなる漢方処方、すなわち
十全大補湯に制癌効果のあることを見い出した。本発明
はこの知見に基づくもので、本発明は十全大補湯よりな
る制癌剤である。十全大補湯は漢方処方の古典(和剤局
方)にその構成生薬、分量、抽出法等が記載されており
、食欲不振、疲労倦怠、病後の体力増強等に使用されて
いるが、制癌効果のあることは従来全く知られていなか
ったことである。
Means to Solve the Problem The present inventors conducted research on the anticancer effects of various Chinese herbal prescriptions, and found that they were found to be effective against cancer. We have discovered that a Chinese herbal formula made from licorice, namely Juzentaihoto, has anticancer effects. The present invention is based on this knowledge, and is an anticancer agent comprising Juzentaihoto. Juzentaihoto's constituent herbal medicines, dosage, extraction method, etc. are described in the classic Chinese herbal prescription (Japanese Pharmacopoeia), and it is used to treat anorexia, fatigue, fatigue, and increase physical strength after illness. It was previously unknown that it had anticancer effects.

十全大?1ItIIhは古典に則って、買占3.Og、
桂皮3、Og、地黄30g、勺薬3.Og、用弓3゜o
g、屈3.Og、当帰3.Og、人参3.0g、決苓3
.Og、甘草1.5gを600ccの水で煎じて350
ccとし滓を取り去り、これを制癌剤として3回に分け
て服用することもできるが、服用のし易さ、携帯の便利
さを考慮して漢方薬エキス製剤としたものを制癌剤とし
て用いることもできる。
Juzendai? 1ItIIh follows the classics and buys 3. Og,
Cinnamon bark 3, Og, rhizome 30g, Chinese herbal medicine 3. Og, bow 3゜o
g, bend 3. Og, return 3. Og, carrot 3.0g, Kessei 3
.. Og, boil 1.5g of licorice with 600cc of water for 350
It is possible to remove the residue from the cc and take it as an anticancer drug in three doses, but it is also possible to use a Chinese herbal medicine extract preparation as an anticancer drug for ease of administration and portability.

たとえば、買置2.5〜3重量部、桂皮3重量部。For example, buy 2.5 to 3 parts by weight and cinnamon 3 parts by weight.

地黄3重量部、荀薬3重量部、用弓3重量部、混3重量
部、当帰3重量部、人参2.5〜3重量部、決苓3重量
部、甘草1.5璽量部を10倍量の水で熱時抽出して得
られた抽出液をI適役、乾燥して制癌剤である十全大補
湯乾燥エキス粉末を得、これに通常の製剤に用いる適当
な賦形剤、補助剤等を加えて製剤製造の常法に従って散
剤、顆粒剤、錠剤、カプセル剤などの製剤にすることが
できる。
3 parts by weight of Rhizoma, 3 parts by weight of Xuyaku, 3 parts by weight of Yōkyu, 3 parts by weight of Mixture, 3 parts by weight of Danggui, 2.5-3 parts by weight of Ginseng, 3 parts by weight of Keili, 1.5 parts by weight of Licorice. The extracted liquid obtained by hot extraction with 10 times the amount of water is dried to obtain Juzentaihoto dry extract powder, which is an anticancer agent, and suitable excipients used in ordinary preparations are added to this powder. , adjuvants, etc. can be added to form preparations such as powders, granules, tablets, and capsules according to conventional methods for manufacturing preparations.

本発明の制癌剤の製造の具体例を示すと次の如くである
A specific example of the production of the anticancer agent of the present invention is as follows.

具体例! 貴重3.Og、桂皮3.0g、地黄3.OgS勺薬3.
Og、用153.0g、胤3.Og、当帰3゜Og、人
参3.0g、決苓3.Og、甘草1.5gの混合生薬に
10倍量すなわち285−の水を加えて1時間、100
℃で加熱抽出し、得られた抽出液をt過後、スプレード
ライして2.2gの乾燥エキス粉末を得た。
Concrete example! Precious 3. Og, cinnamon 3.0g, rhizome 3. OgS medicine 3.
Og, 153.0g, 3 seeds. Og, Toki 3゜Og, Ginseng 3.0g, Kessai 3. Add 10 times the amount of water (285 -
Extraction was carried out by heating at .degree. C., and the resulting extract was filtered and spray-dried to obtain 2.2 g of dry extract powder.

発明の効果 本発明の制癌剤の制癌作用について実験例を挙げて説明
する。
Effects of the Invention The anticancer effect of the anticancer agent of the present invention will be explained by giving experimental examples.

実験例 ■使用動物:ICn系雄性マウス。Experimental example ■Animal used: ICn strain male mouse.

■腫瘍細胞+ICR系マウスにて腫瘍の継代を行ってい
るエーリツヒ(Ehrlich)腹水癌細胞を用いた。
(2) Tumor cells + Ehrlich ascites cancer cells whose tumors were passaged in ICR mice were used.

■実験方法・エーリツヒ(Ehrlich)fil水癌
水胞細胞下EACと称する)を移植した8日後のマウス
から腫瘍細胞を採取し、2X10 細胞10. :2t
ll/マウスになるように生理食塩水で希釈して、マウ
スの腹腔内に移植し、24時間後から具体例1で得られ
た本発明の制癌剤を、100.200および300mg
/kgの投与[18藍回、lθ日日間生理食塩水に溶解
比て腹腔内投与し、生存日数および延命率上り制癌作用
を判定した。コントロールは、本発明の制癌剤を含まな
い生理食塩水を1日、1kgあたり0.25m1!腹腔
内投与した。その結果を第1表に示す。
■Experimental method - Tumor cells were collected from mice 8 days after transplantation of Ehrlich fil (referred to as EAC), and 2×10 cells 10. :2t
The anticancer agent of the present invention obtained in Example 1 was diluted with physiological saline to give a concentration of 100, 200 and 300 mg after 24 hours.
The drug was dissolved in physiological saline and administered intraperitoneally for 18 indigo and lθ days, and survival days and survival rate increase and anticancer effect were determined. As a control, physiological saline containing no anticancer drug of the present invention was administered at 0.25ml/kg per day! It was administered intraperitoneally. The results are shown in Table 1.

第1表 生存日数平均値の下の数字は、平均値に対する標準誤差
を示す。
The numbers below the mean survival days in Table 1 indicate the standard error of the mean.

第1表から明らかなように本発明の制癌剤(よ、マウス
の生存率を上げており、制癌効果が認められた。
As is clear from Table 1, the anticancer agent of the present invention increased the survival rate of mice, and an anticancer effect was observed.

次に、本発明の制癌剤の経口投与での急性毒性試験をd
dY系雄性マウス、及びウィスター(W 1star)
系雄性ラットを用いて行ったところ、具体例1で得た本
発明の制癌剤は、15g/kg(投与限界)の経口投与
でも、死亡例を与えなかった。
Next, an acute toxicity test for oral administration of the anticancer agent of the present invention was conducted on d
dY male mice and Wistar (W 1star)
When tested using male rats, the anticancer agent of the present invention obtained in Example 1 did not cause death even when administered orally at a dose of 15 g/kg (dose limit).

このように、本発明の制癌剤は、極めて毒性が低く安全
性の高いものである。尚、十全大補湯は古来より現在に
至るまで漢方薬として用いられていることからみて、副
作用が少ないことがわかる。
Thus, the anticancer agent of the present invention has extremely low toxicity and high safety. Furthermore, since Juzentaihoto has been used as a Chinese herbal medicine since ancient times to the present, it can be seen that it has few side effects.

本発明における実験データ及び急性毒性試験の結果から
考えて、本発明の制癌剤の有効投与量は、患者の年令、
体重、疾患の程度によっても異なるが、通常成人量で乾
燥エキス粉末量として!日量1〜10gを症状に合わせ
て、1日3回に分けての服用が適当と認められる。
Considering the experimental data and the results of acute toxicity tests in the present invention, the effective dose of the anticancer agent of the present invention is determined by the age of the patient,
Although it varies depending on body weight and degree of disease, it is usually used as an adult amount as a dry extract powder amount! It is considered appropriate to take a daily dose of 1 to 10 g divided into three times a day depending on the symptoms.

次に、実施例を示して、具体的に説明するが、本発明は
、これより制限されるものではない。
Next, examples will be shown and specifically explained, but the present invention is not limited thereto.

実施例! 上記の具体例1により製造した薬剤200gを乳糖89
g及びステアリン酸マグネシウムIgと混合し、この混
合物を単発式打錠機にて打錠して、直径20mm、重I
約2.3gのスラッグ錠を作りこれを、オシレーターに
て粉砕し、整粒し、篩別して20〜50メツシユの粒子
の良好な顆粒剤を得た。
Example! 200g of the drug produced according to the above specific example 1 was added to 89g of lactose.
g and magnesium stearate Ig, and this mixture was compressed using a single-shot tablet machine to form tablets with a diameter of 20 mm and a weight of Ig.
Approximately 2.3 g of slug tablets were prepared, pulverized with an oscillator, sized, and sieved to obtain good granules of 20 to 50 mesh particles.

この顆粒剤は、症状に合わせて1同量0.5〜45g(
本発明の制癌剤の乾燥エキス粉末重量として0.34〜
3.lOgに相当)を1日3回服用する。
This granule is available in an equal amount of 0.5 to 45 g (
The dry extract powder weight of the anticancer agent of the present invention is 0.34~
3. (equivalent to lOg) three times a day.

実施例2 上記の具体例1により製造した薬剤200gを微結晶セ
ルロース20gおよびステアリン酸マグネシウム5gと
混合し、この混合物を単発式打鍵機にて打錠して直径7
繭1、重量225Bの錠剤を製造した。本錠剤!綻中に
は本発明の制癌剤の乾燥エキス粉末を200mg含有す
る。本錠剤は、症状に合わせて1目量2〜16錠を1日
3回服用す実施例3 上記の具体例1により製造した薬剤500mgを硬カプ
セルに充填した。本カプセルは、症状に合わせて2〜2
oカプセルを1日3回に分けて服用する。
Example 2 200 g of the drug produced according to Example 1 above was mixed with 20 g of microcrystalline cellulose and 5 g of magnesium stearate, and this mixture was compressed into tablets with a single-shot key press to form tablets with a diameter of 7.
A tablet having 1 cocoon and a weight of 225B was produced. Book tablets! The solution contains 200 mg of dry extract powder of the anticancer agent of the present invention. Example 3 The tablets are taken in doses of 2 to 16 tablets three times a day depending on the symptoms. 500 mg of the drug produced in Example 1 above was filled into hard capsules. This capsule takes 2 to 2 doses depending on the symptoms.
Take o capsules in 3 divided doses a day.

Claims (1)

【特許請求の範囲】[Claims] 十全大補湯よりなる制癌剤Anticancer drug made from Juzentaihoto
JP59233310A 1984-11-07 1984-11-07 Carcinostatic agent Granted JPS61112027A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP59233310A JPS61112027A (en) 1984-11-07 1984-11-07 Carcinostatic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59233310A JPS61112027A (en) 1984-11-07 1984-11-07 Carcinostatic agent

Publications (2)

Publication Number Publication Date
JPS61112027A true JPS61112027A (en) 1986-05-30
JPH0469618B2 JPH0469618B2 (en) 1992-11-06

Family

ID=16953118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59233310A Granted JPS61112027A (en) 1984-11-07 1984-11-07 Carcinostatic agent

Country Status (1)

Country Link
JP (1) JPS61112027A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071521A (en) * 1989-09-04 2000-06-06 Kim; Song Bae Pharmaceutical composition having an antitumor activity and a process for preparation thereof
JP2004203855A (en) * 2002-06-24 2004-07-22 Akira Awaya Prophylactic and therapeutic method for allergic rhinitis/conjunctivitis, skin allergy and atopic dermatitis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071521A (en) * 1989-09-04 2000-06-06 Kim; Song Bae Pharmaceutical composition having an antitumor activity and a process for preparation thereof
JP2004203855A (en) * 2002-06-24 2004-07-22 Akira Awaya Prophylactic and therapeutic method for allergic rhinitis/conjunctivitis, skin allergy and atopic dermatitis
JP4721626B2 (en) * 2002-06-24 2011-07-13 昭 粟屋 Prevention and treatment of allergic rhinitis / conjunctivitis or skin allergy and atopic dermatitis

Also Published As

Publication number Publication date
JPH0469618B2 (en) 1992-11-06

Similar Documents

Publication Publication Date Title
CN101254247B (en) Pharmaceutical combination with depression resistance and angst resistance effect and method of preparing the same
JPS5936619A (en) Carcinostatic adjuvant
CN100469377C (en) Nankang soft capsule for treating prostatitis
JPH04243832A (en) Treating agent for autoimmune disease
CN101088542A (en) Compound Chinese medicine prepn for treating chest obstruction
JPH02255622A (en) Carcinostatic assistant
US5055297A (en) Immunopotentiator
CN1985891A (en) Compound Chinese medicine preparation with liver protecting function and its preparing process
JPS61112027A (en) Carcinostatic agent
JPH01246224A (en) Remedy for dementia
JPS6025933A (en) Agent for mitigating symptoms of cancer
JPS61115029A (en) Carcinostatic agent
CN101890063A (en) Chinese medicament for reducing blood sugar and preparation method thereof
JPS61109733A (en) Carcinostatic agent
CN110755601A (en) Kidney bean agglutinin plant medicine composition for treating HIV/AIDS immune reconstitution defect and preparation method and application thereof
CN1318057C (en) Method for preparing Chinese medicine formulation for treating gynaecological disease
JPH0469617B2 (en)
JPS6256435A (en) Coronary vasodilator
JPH02300131A (en) Carcinogenesis inhibitor
JPH0232025A (en) Carcinostatic adjuvant
JPH0643327B2 (en) Immunostimulant
CN104055963A (en) Fat loss traditional Chinese medicine composition and preparation method thereof
JPH01207243A (en) Inhibitor of blood platelet aggregation
JPH02255621A (en) Hypotensor
CN109157632B (en) Formula and preparation method of granules for treating epigastric pain